Anti–PD-1 along with anti–CTLA-4 inhibitors offer superior toxicity profiles against lung cancer cells, longer overall survival rates, and higher objective response rates when compared with chemotherapy (66). The gene discussed is CTLA4; the disease is lung carcinoma.